Cargando…

Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma

Immunogenic cell death (ICD) is a form of cell death that stimulates the immune system to produce an immune response by releasing tumour-associated antigens and tumour-specific antigens and is considered to play an important role in tumour immunotherapy. In the present study, we identified two ICD-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zong, Yuan, Cao, Yu, Zhang, Ding, Guan, Xiaoqing, Zhang, Fengyi, Shen, Zhubin, Yin, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241935/
https://www.ncbi.nlm.nih.gov/pubmed/37277499
http://dx.doi.org/10.1038/s41598-023-35745-w
_version_ 1785054101550137344
author Zong, Yuan
Cao, Yu
Zhang, Ding
Guan, Xiaoqing
Zhang, Fengyi
Shen, Zhubin
Yin, Fei
author_facet Zong, Yuan
Cao, Yu
Zhang, Ding
Guan, Xiaoqing
Zhang, Fengyi
Shen, Zhubin
Yin, Fei
author_sort Zong, Yuan
collection PubMed
description Immunogenic cell death (ICD) is a form of cell death that stimulates the immune system to produce an immune response by releasing tumour-associated antigens and tumour-specific antigens and is considered to play an important role in tumour immunotherapy. In the present study, we identified two ICD-related subtypes in osteosarcoma (OS) by consensus clustering. The ICD-low subtype was associated with favourable clinical outcomes, abundant immune cell infiltration, and high activity of immune response signalling. We also established and validated an ICD-related prognostic model, which could not only be used to predict the overall survival of OS patients but was also found to be closely related to the tumour immune microenvironment of OS patients. Overall, we established a new classification system for OS based on ICD-related genes, which can be used to predict the prognosis of OS patients and to select appropriate immunotherapy drugs.
format Online
Article
Text
id pubmed-10241935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102419352023-06-07 Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma Zong, Yuan Cao, Yu Zhang, Ding Guan, Xiaoqing Zhang, Fengyi Shen, Zhubin Yin, Fei Sci Rep Article Immunogenic cell death (ICD) is a form of cell death that stimulates the immune system to produce an immune response by releasing tumour-associated antigens and tumour-specific antigens and is considered to play an important role in tumour immunotherapy. In the present study, we identified two ICD-related subtypes in osteosarcoma (OS) by consensus clustering. The ICD-low subtype was associated with favourable clinical outcomes, abundant immune cell infiltration, and high activity of immune response signalling. We also established and validated an ICD-related prognostic model, which could not only be used to predict the overall survival of OS patients but was also found to be closely related to the tumour immune microenvironment of OS patients. Overall, we established a new classification system for OS based on ICD-related genes, which can be used to predict the prognosis of OS patients and to select appropriate immunotherapy drugs. Nature Publishing Group UK 2023-06-05 /pmc/articles/PMC10241935/ /pubmed/37277499 http://dx.doi.org/10.1038/s41598-023-35745-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zong, Yuan
Cao, Yu
Zhang, Ding
Guan, Xiaoqing
Zhang, Fengyi
Shen, Zhubin
Yin, Fei
Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
title Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
title_full Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
title_fullStr Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
title_full_unstemmed Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
title_short Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
title_sort immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241935/
https://www.ncbi.nlm.nih.gov/pubmed/37277499
http://dx.doi.org/10.1038/s41598-023-35745-w
work_keys_str_mv AT zongyuan immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma
AT caoyu immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma
AT zhangding immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma
AT guanxiaoqing immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma
AT zhangfengyi immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma
AT shenzhubin immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma
AT yinfei immunogeniccelldeathrelatedclassificationsguideprognosisandimmunotherapyinosteosarcoma